Posted by cv6-admin
CV6 Therapeutics
Rebecca Eakin MSc has 5 years of experience in the field of biomedical science and cancer therapeutics. Rebecca joined CV6 Therapeutics in January 2025, following the achievement of a Master of Science by Research in Cancer Medicine (Distinction). Rebecca’s Masters research focused on furthering our understanding of the mechanisms of DNA uracilation and potential application […]
Posted by cv6-admin
CV6 Therapeutics
Udai Banerji, MD, PhD is Deputy Director of the Drug Development Unit, a joint initiative between the Institute of Cancer Research (ICR), London, and The Royal Marsden NHS Foundation Trust. He is Professor of Molecular Cancer Pharmacology at the ICR and a group leader of the Clinical Pharmacodynamics Biomarker Group, Clinical Pharmacology & Trials and […]
Posted by cv6-admin
CV6 Therapeutics
Professor Iain McInnes CBE is Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow. Professor McInnes is an internationally-recognised leader in global research into rheumatoid and psoriatic arthritis having led numerous clinical trials and pathogenesis investigation […]
Posted by pbd-admin
CV6 Therapeutics
Dr Wilson, has over 20 years of experience in cancer research projects focused on identifying mechanisms to improve the effectiveness of chemotherapeutic agents in human cancers. Since 2014, he has held the position of Scientific Director of Drug Development at CV6 Therapeutics (NI) Ltd. Dr Wilson’s research has focused on cellular signaling pathways and the […]
Posted by pbd-admin
CV6 Therapeutics
Dr Lauren Cairns PhD is a research scientist with almost 10 years experience in cancer biology. The primary focus of her research experience was identifying novel repurposed combination therapies for the treatment of paediatric cancers such as AML, ALL and Medulloblastoma. Lauren also successfully implemented a robust multiplex drug screening approach which was later adopted […]
Posted by pbd-admin
CV6 Therapeutics
Dr. Kylie A. McLaughlin PhD has 17 years of experience in the field of biomedical science and oncology. Kylie was the first scientist to join the CV6 Therapeutics R&D Team in 2015. Kylie’s research expertise spans drug development, cancer drug resistance mechanisms, DNA damage, cell death, and nucleotide metabolism. At CV6, Kylie has been actively […]
Posted by pbd-admin
CV6 Therapeutics
Dr Declan Doherty PhD has over 16 years of experience working in both academic and industrial research laboratories. He has worked at Ulster University, Queens University Belfast, Fusion Antibodies PLC and Almac Diagnostics Ltd. Since November 2022, he has held the position of Senior Scientist at CV6 Therapeutics (NI) Ltd where he is currently investigating […]
Posted by pbd-admin
CV6 Therapeutics
Sebastian Stintzing, MD, currently serves as a distinguished Professor of Medicine and leads the Department of Hematology, Oncology, and Tumor Immunology within the CCM at Charité Universitaetsmedizin Berlin. His professional focus involves identifying predictive and prognostic biomarkers in gastrointestinal cancer treatment. In 2012, he was awarded the esteemed Research Fellowship Award from “Deutsche Krebshilfe” (German […]
Posted by cv6-admin
CV6 Therapeutics
Chris E. Rivera is currently the President, CEO and Chairman of the Board of Nativis Inc. He has over 30 years’ experience in the development and manufacturing of pharmaceutical and medical devices. Whilst at the Washington Biotechnology and Biomedical Association he established the commercialization programs of more than 400 emerging biotechnology companies. Chris was the […]
Posted by cv6-admin
CV6 Therapeutics
Richard ‘Dick’ Milliken is the Chairman of Catalyst Inc., (formerly the Northern Ireland Science Park), and the Lotus Group Ltd. He is a Non-Executive Director of Ryanair Plc and the Bank of Ireland Mortgage Bank. In addition, Dick mentors a number of smaller early stage growth companies based in Northern Ireland. Previously, Dick was the […]
